Stereotaxis, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STXS research report →
Range $3.5 – $3.5
Price Chart
About the company
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices.
- CEO
- David L. Fischel
- IPO
- 2004
- Employees
- 131
- HQ
- St. Louis, MO, US
Get TickerSpark's AI analysis on STXS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $95.03M
- P/E
- -3.89
- PEG
- -0.26
- P/S
- 3.01
- P/B
- 4.54
- EV/EBITDA
- -4.68
- Div Yield
- 0.00%
- Gross Margin
- 52.53%
- Op Margin
- -69.36%
- Net Margin
- -70.86%
- ROE
- -115.83%
- ROIC
- -42.29%
Latest fiscal year · YoY change
- Revenue
- $32.38M+20.3%
- Gross Profit
- $17.07M+17.0%
- Op Income
- $-22,112,000
- Net Income
- $-21,643,000+10.0%
- EPS
- $-0.25+16.7%
- OCF Growth
- -61.1%
- FCF Growth
- -61.5%
- 52W High
- $2.86
- 52W Low
- $0.80
- 50D MA
- $1.09
- 200D MA
- $1.60
- Beta
- 1.40
- RSI (14)
- 48
- Avg Volume
- 701.15K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Stereotaxis posted 20% revenue growth in Q3 as first GenesisX and Synchrony commercialization began to gain traction, but catheter supply constraints and acquisition-related costs kept losses and cash burn elevated.· November 10, 2026
- Q3 revenue was $8.9 million, up 20% year over year and up 16% sequentially; system revenue rose to $3 million and recurring revenue was $5.9 million.
- Gross margin was 45% in the quarter, with system gross margin at 15% and recurring gross margin at 59%; management said margins should stay near these levels near term, with expansion potential in 2027-2028.
- GenesisX and Synchrony are starting to contribute commercially, with first U.S. GenesisX installation planned this month, first Europe installation soon after, and multiple Synchrony systems sold and installed.
- MAGIC catheter supply remained the biggest operational constraint; Q3 disposable shipments did not improve versus Q2, and management entered Q4 with about $1.9 million of backlog it could not convert to revenue.
- The company closed a convertible note financing for $12 million upfront, with up to another $12 million available later, which management said gives it a path to profitability next year and pro forma cash of $16 million.
Revenue in the third quarter of 2026 totaled $8.9 million, up 20% from $7.5 million a year ago and up 16% sequentially from $7.7 million in Q2. System revenue was $3 million versus $1.9 million last year, helped by partial revenue recognition from the first GenesisX sale in the U.S., the first Genesis sale in China, and the first full quarter of Synchrony sales. Recurring revenue was $5.9 million, up 6% year over year but down 4% sequentially. Gross margin was 45% of revenue; system and recurring gross margins were 15% and 59%, respectively. Operating loss and net loss were both $6.5 million, flat versus last year, while adjusted operating loss and adjusted net loss were $5.1 million and $5.2 million versus $2.5 million and $2.4 million a year ago. Cash flow was negative $6.5 million in the quarter, including $2.6 million from the core business and $3.9 million related to Robocath acquisition payments. Cash and cash equivalents were $4 million at September 30, and pro forma cash would be $16 million after the new financing. Management expects near-term growth in recurring revenue and more consistent capital sales, with a pathway to profitability next year.
David Fischel framed the quarter as an early stage but important inflection point in two structural shifts: moving to easier-to-install capital systems and building a recurring catheter revenue base. He said GenesisX and Synchrony are beginning to show commercial impact and emphasized upcoming milestones, including the first U.S. GenesisX installation, European installation, and broader interoperability with standard X-ray systems. His tone was optimistic and unusually emphatic, saying he has never felt as proud of the company or as confident about the opportunity, while also acknowledging real stresses and challenges.
Kimberly Peery highlighted that Q3 revenue rose to $8.9 million, with system revenue at $3 million and recurring revenue at $5.9 million. She said gross margin was 45%, system margin was 15%, and recurring margin was 59%, with both affected by overhead absorption at low volume; she expects margins to stay around these levels near term, with significant expansion potential in 2027 and 2028. She also said adjusted operating expenses were $9.1 million, and management sees roughly $8 million per quarter as a reasonable future run rate excluding noncash and one-time items. Cash burn was $6.5 million in the quarter, and the company ended with $4 million in cash before the financing, which adds $12 million upfront and potentially another $12 million later.
Analysts focused on three main issues: rising physician interest in robotics, the catheter supply bottleneck, and what the Canon partnership means for GenesisX. Management said conference attendance and physician engagement have improved, but adoption still requires sites to transition away from their old ecosystem and work through supply constraints, and David Fischel also noted PFA is creating mindshare distraction rather than a direct competitive threat. On supply, he said Osypka has underperformed badly, that Europe is being shifted to alternative catheters, and that redundant supply could be in place in the earlier part of 2027; on Canon, he said the collaboration should make hospitals more comfortable and could create co-marketing and technology synergies. On Synchrony, he said near-term revenue around $1 million a quarter is reasonable, with the potential for a few million dollars in some quarters as more systems are sold and later as service/software revenue begins to build.
The call showed real commercial progress from GenesisX and Synchrony, with the company saying both platforms are now generating initial revenue and have sizable pipelines. Management also pointed to improving physician interest, stronger conference attendance, and a broader interoperability strategy that could make GenesisX easier to adopt across hospitals. The financing reduces near-term cash pressure and management believes it can bridge the business to profitability within the next year.
The biggest risk remains supply: MAGIC catheter production has not ramped as expected, and management said Q3 shipments did not improve versus Q2, leaving about $1.9 million of backlog unconverted at quarter-end. The company is still posting losses and negative cash flow, and Q3 adjusted losses widened from last year due to Robocath-related costs and transaction expenses. Management also acknowledged that product transitions, regulatory steps, and the need to prove new systems in real-world use could delay broader commercial momentum.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 66.4%
- Shares Outstanding
- 100.20M
- Float Shares
- 66.50M
of shares held by institutions
112 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Dafna Capital Management LLC | 13.68M | 0 |
| Blackrock, Inc. | 4.38M | ▼ 12.63K |
| Lagoda Investment Management, L.P. | 4.12M | ▼ 227.80K |
| Vanguard Group Inc | 3.69M | ▲ 251.66K |
| Vanguard Capital Management LLC | 3.01M | ▼ 34.93K |
| Arbiter Partners Capital Management LLC | 2.88M | 0 |
| Geode Capital Management, LLC | 1.90M | ▲ 9.51K |
| Archon Capital Management LLC | 1.23M | 0 |
| Warberg Asset Management LLC | 1.13M | ▲ 22.48K |
| State Street Corp | 910.97K | ▼ 5.81K |
| Integrity Alliance, LLC. | 699.02K | ▲ 699.02K |
| Alphacentric Advisors LLC | 600.00K | 0 |
Held by 92 ETFs
Biggest fund positions in STXS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Benfer David | buy | 30,000 |
| Nov 17, 26 | Menawat Arun Swarup | buy | 121,561 |
| Nov 17, 26 | Isaac Paul J | buy | 300 |
| Nov 16, 26 | Isaac Paul J | buy | 13,000 |
| Nov 9, 26 | DAFNA Capital Management LLC | buy | 0 |
| Nov 9, 26 | Fischel Nathan | buy | 0 |
| Jul 1, 26 | SHAMIR NACHUM | other | 43,103 |
| Jul 1, 26 | Benfer David | other | 43,103 |
| Jul 1, 26 | Levin Ross B | other | 43,103 |
| Jul 1, 26 | Curet Myriam | other | 43,103 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our STXS coverage
Recent articles, reports, and earnings notes.
No research on STXS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate STXS report →What Stereotaxis (STXS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 11
Stereotaxis, Inc. (STXS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 11
Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates
globenewswire.com · Nov 10
Stereotaxis Announces Convertible Note Financing of Up To $24 Million
globenewswire.com · Nov 10
First-in-Human Coronary Intervention Study Results of Robocath's Next-Generation Robotic System Highlighted at TCT
globenewswire.com · Nov 2
Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology
globenewswire.com · Oct 30
Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia
globenewswire.com · Oct 22
Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026
globenewswire.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.